Korea Faces FTA Dilemma As It Seeks To Balance Pricing Concerns
South Korean pharma firms are facing a dilemma due to the country's Free Trade Agreement renegotiations with the US, under which drug pricing is not the only difficulty being raised by foreign companies seeking reforms. Despite ongoing government efforts to attract global pharma companies, such firms are also still finding it tough to search for alliance partners in the country.
You may also be interested in...
After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.